SAMSUNG-ELECTRONICS
9.9.2021 10:02:12 CEST | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today announced that four of its System LSI products received product carbon footprint label certification from the Carbon Trust, the first of Samsung’s logic chips to do so.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210909005409/en/
Having received the semiconductor industry’s first carbon footprint accreditation for memory chips from the Carbon Trust in 2019, Samsung has now broadened its ESG (Environmental, Social, and Governance) spectrum with this global recognition of ‘eco-friendly’ logic chips. Samsung also grabbed the industry’s first triple Carbon Trust Standard for Carbon, Water and Waste in June 2021.
The Carbon Trust is an independent and expert partner of organizations around the world that advises businesses on their opportunities in a sustainable, low carbon world. The Carbon Trust also measures and certifies the environmental footprint of organizations, supply chains and products.
Of the various certification categories of the Carbon Trust, Samsung’s System LSI products received the CO2 Measured product carbon footprint label. The label certifies the chip’s carbon footprint, which informs consumers of the impact that the product and its manufacturing process have on the environment.
Receiving the CO2 Measured label is a critical first step for carbon reduction, since it verifies the current carbon emissions of the product with globally recognized specifications (PAS 2050), which Samsung can use as a benchmark to measure future carbon reductions.
Correctly measuring the carbon footprint of a product requires extensive effort and time. It involves calculating the amount of carbon emitted from fabricating raw subsidiary materials and transporting the product, as well as the carbon emission from using electricity, water, and gas. The hundreds of fabrication processes needed to make a semiconductor chip adds to the complication.
“We’re pleased to have worked with Samsung on this step in its sustainability journey,” said Hugh Jones, managing director at the Carbon Trust Advisory. “The Carbon Trust’s Carbon Measured certification is a clear and credible indicator for consumers that the carbon footprint of these products have been independently verified, as well as a baseline for Samsung to compare against as they work towards reducing their emissions in the future.”
The four products to receive certification include a variety of Samsung’s System LSI chips, from mobile processors to image sensors. The Exynos 2100, one of the four products to receive certification, is a high-performance mobile processor built with the most advanced 5-nanometer (nm) extreme ultra-violet (EUV) process node. The 0.7-micrometer (μm)-pixel image sensor ISOCELL HM2, DTV SoC (S6HD820), and TCON (S6TST21) also received certification by the Carbon Trust.
Including the four chips, Samsung has so far received certifications for fourteen of its semiconductor products from the Carbon Trust.
“We are thrilled to be globally acknowledged for our eco-friendly efforts,” said Seong-dai Jang, senior vice president and head of DS Corporate Sustainability Management Office at Samsung Electronics. “We will continue to fulfill our carbon reduction goals and expand our efforts to a wider range of eco-friendly, high-performance products to meet the global standards for a sustainable future.”
Exynos 2100
Based on 5nm EUV process technology, the Exynos 2100 is Samsung’s first 5G-integrated flagship mobile processor for premium mobile devices. The Exynos 2100 performs up to 26-trillion-operations-per-second (TOPS) with more than twice the power efficiency than the previous generation.
ISOCELL HM2
The ISOCELL HM2 is a 0.7μm-pixel image sensor that opened up the market for ultra-high resolutions. The 108MP-sensor is around 15 percent smaller than the 0.8μm-based predecessors, and reduces the height of the camera module by 10 percent, while featuring faster autofocus, nine-pixel binning and 3x lossless zoom.
DTV SoC (S6HD820)
Samsung’s DTV SoC (S6HD820) is an essential component in television as picture quality evolves from 4K to 8K standard. The DTV SoC’s NPU (neural processing unit) allows AI technology to improve picture quality and audio processing.
TCON (S6TST21)
A TCON takes video data from the DTV SoC and converts it according to the demands of the DDI (Display Driver IC). The data transmission speed of the TCON is important when it comes to quickly transmitting high-resolution video data to the DDI. Samsung’s TCON (S6TST21) integrates two 8K 60-hertz (Hz) chips to minimize energy loss.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005409/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
